Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy

Journal of the American College of Cardiology

Volumn 68, Issue 3, 2016, Pages 286-293

  Stratz, Christian ^a   Bömicke, Timo ^a   Younas, Iris ^a   Kittel, Anja ^b   Amann, Michael ^a   Valina, Christian M ^a   Nührenberg, Thomas ^a   Trenk, Dietmar ^a   Neumann, Franz Josef ^a   Hochholzer, Willibald ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

clopidogrel; percutaneous coronary intervention; prasugrel; reticulated platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

AGE DISTRIBUTION; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY STENTING; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENETIC POLYMORPHISM; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IMMATURE PLATELET FRACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULATED PLATELET; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; AGED; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; STENT; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET COUNT; PYRIDINES; STENTS; TREATMENT OUTCOME;

EID: 84979948952     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.04.056     Document Type: Article

References (36)

1. 1 Siller-Matula, J.M., Trenk, D., Schror, K., et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. J Am Coll Cardiol Intv 6 (2013), 1111–1128.
2. 2 Gurbel, P.A., Bliden, K.P., Hiatt, B.L., O'Connor, C.M., Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003), 2908–2913.
3. 3 Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
4. 4 Bonello, L., Tantry, U.S., Marcucci, R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56 (2010), 919–933.
5. 5 Hochholzer, W., Trenk, D., Bestehorn, H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006), 1742–1750.
6. 6 Sibbing, D., Braun, S., Morath, T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009), 849–856.
7. 7 Stone, G.W., Witzenbichler, B., Weisz, G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
8. 8 Hochholzer, W., Trenk, D., Fromm, M.F., et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55 (2010), 2427–2434.
9. 9 Trenk, D., Hochholzer, W., Fromm, M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008), 1925–1934.
10. 10 Hochholzer, W., Valina, C.M., Bomicke, T., et al. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome. Thromb Haemost 114 (2015), 109–114.
11. 11 Droppa, M., Tschernow, D., Muller, K.A., et al. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One, 10, 2015, e0121620.
12. 12 Frelinger, A.L. 3rd, Bhatt, D.L., Lee, R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61 (2013), 872–879.
13. 13 Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009), 849–857.
14. 14 Bernlochner, I., Goedel, A., Plischke, C., et al. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J 36 (2015), 3202–3210.
15. 15 Perl, L., Lerman-Shivek, H., Rechavia, E., et al. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63 (2014), 513–517.
16. 16 Guthikonda, S., Alviar, C.L., Vaduganathan, M., et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52 (2008), 743–749.
17. 17 Ibrahim, H., Nadipalli, S., DeLao, T., et al. Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. J Thromb Thrombolysis 33 (2012), 137–142.
18. 18 Grove, E.L., Hvas, A.M., Kristensen, S.D., Immature platelets in patients with acute coronary syndromes. Thromb Haemost 101 (2009), 151–156.
19. 19 Cesari, F., Marcucci, R., Gori, A.M., et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost 109 (2013), 846–853.
20. 20 Ibrahim, H., Schutt, R.C., Hannawi, B., et al. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol 64 (2014), 2122–2129.
21. 21 Ingram, M., Coopersmith, A., Reticulated platelets following acute blood loss. Br J Haematol 17 (1969), 225–229.
22. 22 Michelson, A.D., The regulation of platelet life span. Michelson, A.D., (eds.) Platelets, 3rd edition, 2013, Academic Press, Amsterdam, the Netherlands, 51–65.
23. 23 Pons, I., Monteagudo, M., Lucchetti, G., et al. Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 85 (2010), 158–163.
24. 24 Hoffmann, J.J., Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 52 (2014), 1107–1117.
25. 25 Hochholzer, W., Amann, M., Titov, A., et al. Randomized comparison of different thienopyridine loading strategies in patients undergoing elective coronary intervention: the ExcelsiorLOAD trial. J Am Coll Cardiol Intv 9 (2016), 219–227.
26. 26 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
27. 27 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35 (2014), 2541–2619.
28. 28 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
29. 29 Bliden, K.P., Dichiara, J., Lawal, L., et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52 (2008), 531–533.
30. 30 Gurbel, P.A., Bliden, K.P., Logan, D.K., et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 62 (2013), 505–512.
31. 31 Morel, O., El Ghannudi, S., Jesel, L., et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 57 (2011), 399–408.
32. 32 Neubauer, H., Kaiser, A.F., Endres, H.G., et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med, 9, 2011, 3.
33. 33 Verdoia, M., Sartori, C., Pergolini, P., et al. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. J Thromb Thrombolysis 41 (2016), 663–670.
34. 34 Grove, E.L., Hvas, A.M., Mortensen, S.B., et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 9 (2011), 185–191.
35. 35 Wurtz, M., Wulff, L.N., Grove, E.L., et al. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res 129 (2012), 434–440.
36. 36 Wallentin, L., Varenhorst, C., James, S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008), 21–30.